Clinical Trials Logo

Clinical Trial Summary

This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care (Intralipid) from 7 up to 90 days to develop Essential Fatty Acid Deficiency (EFAD). Additionally, this study design will evaluate the safety and efficacy of using Clinolipid or Intralipid in a pediatric population.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

  • Essential Fatty Acid Deficiency (EFAD)

NCT number NCT04555044
Study type Interventional
Source Baxter Healthcare Corporation
Status Completed
Phase Phase 4
Start date January 22, 2021
Completion date November 16, 2022

See also
  Status Clinical Trial Phase
Terminated NCT02476994 - Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion Phase 4